Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:28 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 877 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Endocrine Clear all
Active, not recruiting Phase 3 Interventional

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557
View directory record Official record
Conditions
Breast Cancer, Early Breast Cancer
Interventions
Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane, Abemaciclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
5,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2037
U.S. locations
111
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 3, 2026, 5:28 PM EST
Terminated Phase 2 Interventional Results available

Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

NCT00929669
View directory record Official record
Conditions
Gonadotroph Adenomas
Interventions
pasireotide LAR
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Nov 3, 2026, 5:28 PM EST
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Nov 3, 2026, 5:28 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes

NCT02398383
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Interventions
Oral Glucose Tolerance Test, Mixed Meal Tolerance Test, Hypoglycemic Clamp
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Nov 3, 2026, 5:28 PM EST
Active, not recruiting Not applicable Interventional

MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ

NCT02352883
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ
Interventions
Magnetic Resonance Imaging, Therapeutic Conventional Surgery, Therapeutic Surgical Procedure, Radiation Therapy, Endocrine Therapy, Quality-of-Life Assessment, Laboratory Biomarker Analysis, Cytology Specimen Collection Procedure
Procedure · Radiation · Drug + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Female only
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
76
States / cities
San Diego, California • San Marcos, California • Greenwich, Connecticut + 56 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Nov 3, 2026, 5:28 PM EST
Completed Phase 2 Interventional Results available

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

NCT00499083
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Genetic + 3 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Nov 3, 2026, 5:28 PM EST
Terminated Not applicable Interventional Results available

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

NCT02149173
View directory record Official record
Conditions
Estrogen Receptor Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Nov 3, 2026, 5:28 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Stress and Pain in People Living With HIV

NCT06784908
View directory record Official record
Conditions
HIV, Depression, Cannabis Use Disorder, Stress, Pain
Interventions
Yale Pain Stress Task (YPST)
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 68 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Nov 3, 2026, 5:28 PM EST
Completed Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

NCT02308020
View directory record Official record
Conditions
Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Brain Metastases
Interventions
Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Duarte, California • La Jolla, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Nov 3, 2026, 5:28 PM EST
Completed Phase 4 Interventional

Minimizing Narcotic Analgesics After Endocrine Surgery

NCT03469310
View directory record Official record
Conditions
Thyroid Cancer, Thyroid Nodule, Thyroid Neoplasms, Thyroid Goitre, Thyroid Diseases, Parathyroid Diseases, Parathyroid Adenoma, Parathyroid Hyperplasia
Interventions
Acetaminophen 500Mg Cap, Tylenol #3 Oral Tablet, Tramadol
Drug
Lead sponsor
Minerva A Romero Arenas
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Nov 3, 2026, 5:28 PM EST
Completed No phase listed Observational

Biomarkers in Blood Samples From Older Breast Cancer Survivors

NCT01138345
View directory record Official record
Conditions
Breast Cancer
Interventions
gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, medical chart review, questionnaire administration
Genetic · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Nov 3, 2026, 5:28 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of ProHydrolase® on the Amino Acid, Intramuscular Anabolic Signaling, and Endocrine Response to Resistance Exercise in Trained Males

NCT04144114
View directory record Official record
Conditions
Amino Acids
Interventions
ProHydrolase®, Whey protein, Placebo
Dietary Supplement
Lead sponsor
Deerland Enzymes
Industry
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Nov 3, 2026, 5:28 PM EST
Recruiting Phase 3 Interventional

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

NCT07578116
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2033
U.S. locations
59
States / cities
Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 3, 2026, 5:28 PM EST
Completed Not applicable Interventional Results available

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

NCT01928186
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis, Run-in (short pre-surgery course) of endocrine-targeted therapy
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Nov 3, 2026, 5:28 PM EST
Withdrawn Not applicable Interventional

Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.

NCT00287456
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes
Interventions
Insulin Pump, Insulin, Oral Glucose Tolerance Test, Whole body Protein Turnover
Device · Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 32 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Nov 3, 2026, 5:28 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy

NCT00004329
View directory record Official record
Conditions
Lipodystrophy
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 5:28 PM EST
Completed No phase listed Observational

Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index

NCT01701050
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Blood collection
Other
Lead sponsor
Janssen Diagnostics, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
18
States / cities
Phoenix, Arizona • Fort Myers, Florida • St. Petersburg, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Nov 3, 2026, 5:28 PM EST
Terminated No phase listed Observational Accepts healthy volunteers

Bone, Endocrine and Lifestyle Longitudinal Study

NCT02063074
View directory record Official record
Conditions
Osteoporosis
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
19 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Nov 3, 2026, 5:28 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Prevalence of Carbohydrate Intolerance in Lean and Overweight/Obese Children

NCT01967849
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Oral Glucose tolerance test
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
7 Years to 21 Years
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 3, 2026, 5:28 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Body's Response to Food Intake in Trained, Older Adults

NCT00798668
View directory record Official record
Conditions
Elderly
Interventions
Liquid Supplements, Solid Supplement
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
60 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Nov 3, 2026, 5:28 PM EST
Active, not recruiting Not applicable Interventional

Enhancing Telemedicine for T2D

NCT06740435
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Enhanced Telemedicine for Type 2 Diabetes, Usual Telemedicine Endocrinology Care for T2D
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 3, 2026, 5:28 PM EST
Terminated Phase 2 Interventional Results available

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

NCT04059484
View directory record Official record
Conditions
Breast Cancer Metastatic
Interventions
Amcenestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
Birmingham, Alabama • Bakersfield, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Nov 3, 2026, 5:28 PM EST
Completed No phase listed Observational

Wearable Sensors and Artificial Intelligence for Carbohydrate Counting

NCT05335889
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
eButton, Continuous Glucose Monitoring (CGM)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Nov 3, 2026, 5:28 PM EST
Terminated Phase 4 Interventional Results available

Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure

NCT04071626
View directory record Official record
Conditions
Heart Failure, Diastolic, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin 5 mg, Placebo oral tablet
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Nov 3, 2026, 5:28 PM EST